List of Excipients in Branded Drug MYLOTARG

Mylotarg Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Mylotarg, or gemtuzumab ozogamicin, is a lyophilized antibody-drug conjugate marketed by Pfizer for CD33-positive acute myeloid leukemia. Its commercial formulation uses a conventional biologic excipient system built around a sugar stabilizer, dextran, surfactant, and sodium chloride. The main commercial opportunities are improved liquid stability, reduced infusion preparation, lower excipient-related risk, pediatric dose flexibility, and biosimilar or follow-on biologic development.

The strongest formulation opportunity is a differentiated presentation that reduces reconstitution steps without changing the antibody-drug conjugate's clinical exposure. Any material formulation change would require analytical comparability, stability data, container-closure studies, and a regulatory strategy under the biologics framework.

What excipients are used in Mylotarg?

Mylotarg is supplied as a sterile, preservative-free, white to off-white lyophilized powder in a single-dose vial. The FDA prescribing information identifies sodium chloride, dextran 40, sucrose, and polysorbate 80 as formulation excipients.[1]

Excipient	Primary formulation role	Commercial or technical issue
Sucrose	Lyoprotectant and stabilizer during freezing and drying	Can support cake formation and protein-conformation stability; concentration affects reconstitution and osmolality
Dextran 40	Bulking agent and stabilizer	May increase viscosity and introduces a polysaccharide-related tolerability and supply consideration
Polysorbate 80	Surfactant that limits interface-induced aggregation and adsorption	Oxidation and hydrolysis can generate degradants that affect protein stability
Sodium chloride	Tonicity and ionic-strength modifier	Affects osmolality, aggregation behavior, and infusion compatibility

Mylotarg is reconstituted with sterile water for injection and then diluted in normal saline before intravenous infusion.[1] The current workflow requires aseptic manipulation, staged dilution, and controlled handling because the product is a cytotoxic antibody-drug conjugate.

Why does Mylotarg need a multi-excipient system?

Gemtuzumab ozogamicin combines a monoclonal antibody with a chemically complex calicheamicin derivative. The formulation must protect the antibody against aggregation, adsorption, oxidation, freeze-concentration effects, and mechanical stress while preserving the conjugate's drug-antibody ratio and linker-payload integrity.

The excipient system must also support:

• Lyophilized cake formation
• Rapid and complete reconstitution
• Low visible and subvisible particle formation
• Acceptable infusion osmolality
• Stability during refrigerated storage
• Compatibility with glass vials, stoppers, and infusion components
• Control of free payload and antibody fragments

The formulation is therefore more difficult to redesign than a conventional small-molecule injectable.

What formulation patents protect Mylotarg?

Mylotarg is regulated as a biologic, so its patent and exclusivity analysis differs from that of an orally administered small molecule. Mylotarg does not have an FDA Orange Book listing in the same manner as a conventional New Drug Application product. Patent disputes are handled through biologic patent-disclosure and litigation procedures, including the Biologics Price Competition and Innovation Act framework, rather than a standard Orange Book Paragraph IV certification.

Publicly visible protection for an antibody-drug conjugate may include several patent families:

1. The anti-CD33 antibody or antibody sequence
2. The calicheamicin payload and linker chemistry
3. Antibody-payload conjugation methods
4. Drug-antibody ratio control
5. Treatment of AML or other CD33-positive malignancies
6. Lyophilized formulations
7. Stability and manufacturing processes
8. Pharmaceutical compositions and dosing regimens

A formulation patent would need to claim a specific combination or concentration range with a measurable technical advantage. Broad claims covering sucrose, dextran, polysorbate 80, or sodium chloride alone would face substantial prior-art exposure.

How strong is the formulation patent opportunity?

The strongest formulation claims would likely focus on a defined technical result rather than the mere presence of a known excipient. Commercially meaningful claim areas include:

• Improved long-term stability at refrigerated conditions
• Reduced aggregation after reconstitution
• Reduced free calicheamicin formation
• Lower particle counts
• Improved recovery from the vial
• Reduced reconstitution time
• Liquid stability that eliminates lyophilization
• Compatibility with a ready-to-administer container
• Improved stability at higher concentration
• Reduced polysorbate degradation
• Reduced viscosity or improved syringeability

A credible patent package would require comparative data against the marketed Mylotarg formulation. Useful data would include SEC-HPLC, CE-SDS, peptide mapping, mass spectrometry, potency, free-payload analysis, subvisible particles, visible particles, and accelerated stability.

When does Mylotarg lose exclusivity?

Mylotarg was first approved in the United States in 2000, withdrawn from the market in 2010, and reapproved in 2017 after a confirmatory development program.[2,3] Its regulatory position is unusual because the product has both an older approval history and a later approval for a revised dosing and indication profile.

Event	Date	Commercial significance
Initial FDA approval	May 17, 2000	Established the original biologic product
Voluntary U.S. withdrawal	October 2010	Removed the product from routine U.S. commercial supply
Reapproval	September 1, 2017	Restored U.S. marketing with revised dosing and indications
Current regulatory category	Biologic, BLA	Biosimilar pathway rather than ANDA pathway

The statutory 12-year reference-product exclusivity concept must be assessed against the product's original pre-2010 biologic approval and its later reapproval. The 2017 action was a reapproval of a previously licensed biological product, not a straightforward first license for a new biologic. A commercial entrant cannot assume that the 2017 date automatically creates a fresh 12-year exclusivity period.

Patent expiration dates must be determined family by family. The relevant patent scope may be narrower than the underlying product concept because antibody, payload, linker, formulation, manufacturing, and method-of-use claims expire on different schedules.

Is Mylotarg listed in the Orange Book?

No. Mylotarg is a biologic licensed under a BLA and is not analyzed through the traditional Orange Book listing system used for NDA products. A generic applicant therefore would not file a conventional Paragraph IV certification against an Orange Book-listed Mylotarg patent.

Can a company file a Paragraph IV challenge to Mylotarg?

No conventional Paragraph IV challenge applies to Mylotarg. A competitor would generally pursue a biosimilar or interchangeable biosimilar application under section 351(k) of the Public Health Service Act. The competitor's strategy would involve reference-product patent information, patent litigation, and the statutory biosimilar exchange process.

What is the FDA regulatory status of Mylotarg?

Mylotarg is approved for specified CD33-positive AML populations. The 2017 approval restored the product for newly diagnosed adults and pediatric patients aged one month and older in combination with chemotherapy, and for relapsed or refractory adults and pediatric patients aged two years and older as a single agent.[3]

The product has a boxed warning addressing hepatotoxicity, including veno-occlusive disease, and serious or fatal infusion-related reactions. These safety risks affect formulation strategy because a modified formulation cannot be evaluated solely on physical stability. Changes in concentration, infusion time, particle profile, or excipient exposure could affect tolerability and pharmacokinetics.

What regulatory pathway applies to an improved Mylotarg formulation?

For Pfizer, an improved formulation would likely require a supplement to the existing BLA. The regulatory package could include:

• Comparative physicochemical characterization
• Forced-degradation studies
• Relative potency and cytotoxicity assays
• Free-payload and linker stability testing
• Pharmacokinetic bridging
• Immunogenicity assessment
• Infusion reaction analysis
• Extractables and leachables
• Container-closure integrity
• Updated manufacturing controls
• Revised handling and administration instructions

A new sponsor developing a biosimilar would need to establish biosimilarity to the reference product. A formulation may differ from the reference formulation if the difference does not prevent biosimilarity and the product meets applicable safety and quality requirements. The sponsor would not need to copy every Mylotarg excipient, but it would need to control clinically relevant differences.

What commercial opportunities exist in Mylotarg excipients?

1. Liquid or concentrated Mylotarg presentation

The current lyophilized format creates hospital pharmacy labor, reconstitution risk, and product wastage. A liquid formulation could reduce preparation time and simplify administration.

The principal barrier is long-term stability. A liquid antibody-drug conjugate must control aggregation, payload release, oxidation, hydrolysis, and adsorption. Candidate strategies may include:

• Alternative sugar systems
• Histidine or phosphate buffering
• Arginine or other aggregation-reducing amino acids
• Poloxamers or alternative nonionic surfactants
• Lower peroxide-load surfactants
• Chelating agents where compatible with the conjugate
• Optimized pH and ionic strength

A liquid product with acceptable refrigerated stability would have the highest potential for hospital-use differentiation.

2. Dextran-reduction strategy

Dextran 40 contributes bulking and stabilization in the lyophilized product. A reformulation that replaces or reduces dextran could improve viscosity, simplify analytical control, and reduce dependence on a polysaccharide excipient.

Possible substitutes include mannitol, trehalose, additional sucrose, glycine, or amino-acid combinations. Each alternative creates tradeoffs:

Replacement approach	Potential benefit	Main development risk
Higher sucrose or trehalose	Stronger protein stabilization	Cake structure and reconstitution behavior
Mannitol	Good bulking and elegant cake	Crystallization can exclude protein from the stabilizing matrix
Glycine	Useful bulking and buffering contribution	May alter aggregation and tonicity
Amino-acid blend	Potential aggregation control	More complex safety and analytical justification
Dextran reduction only	Preserves much of the existing platform	May not produce a sufficiently differentiated product

3. Polysorbate 80 replacement

Polysorbate 80 is widely used in biologics but can degrade through oxidation and hydrolysis. A reformulation using polysorbate 20, poloxamer 188, or a newer low-peroxide surfactant could improve stability if it does not increase aggregation or alter payload integrity.

This area has licensing potential for excipient suppliers and formulation technology companies. The key evidence would be a direct comparison under agitation, light exposure, freeze-thaw, and accelerated-temperature conditions.

4. Ready-to-administer and pharmacy-ready formats

Mylotarg is administered in oncology centers, where preparation simplicity has operational value. Commercial concepts include:

• Pharmacy-ready single-dose bags
• Dual-chamber vials
• Premeasured reconstitution systems
• Small-volume concentrated vials
• Closed-system transfer-compatible presentations
• Reduced-waste dose presentations for pediatric patients

These opportunities may be protected through container-closure, packaging, device, or process patents even where the excipient composition is not novel.

5. Pediatric dose flexibility

Mylotarg is used in pediatric AML populations with weight- or body-surface-area-based dosing. A lower-concentration or more flexible presentation could reduce dose-rounding waste and improve preparation accuracy.

The opportunity is strongest for:

• Lower fill-volume vials
• More concentrated liquid presentations
• Multiple vial strengths
• Pediatric-compatible administration kits
• Improved dose recovery from partially used preparation materials

Because Mylotarg is a single-dose product, dose efficiency is a direct hospital economic issue.

Which companies are challenging Mylotarg?

No widely established FDA-approved Mylotarg biosimilar or interchangeable biosimilar has been identified in the public FDA biosimilar approval record through the current regulatory landscape. The competitive field is therefore more likely to develop through:

• Biosimilar ADC developers
• Oncology-focused biologics companies
• Contract development and manufacturing organizations
• Excipient and surfactant suppliers
• ADC platform companies with anti-CD33 programs
• Alternative CD33-directed therapies

The biosimilar barrier is higher than for a conventional monoclonal antibody because the product includes a heterogeneous conjugate, linker chemistry, payload, and drug-antibody ratio distribution. A developer must characterize both the antibody component and the conjugated small-molecule component.

What manufacturing and intellectual-property barriers affect Mylotarg?

Mylotarg's manufacturing process is a significant barrier to entry. Key technical controls include:

• Antibody expression and purification
• Site and degree of conjugation
• Drug-antibody ratio distribution
• Free antibody and free payload
• Residual solvents and reagents
• Linker stability
• Aggregation and fragmentation
• Sterility and endotoxin
• Potency against CD33-positive cells
• Payload release after internalization

A biosimilar applicant could use a different conjugation process or excipient system, but the final product must remain highly similar and clinically non-meaningful differences must be excluded.

Patent risk is distributed across product and process claims. Even after core composition claims expire, manufacturing know-how, analytical methods, trade secrets, and regulatory experience can delay practical market entry.

How does Mylotarg compare with other CD33-directed therapies?

Product or approach	Modality	Formulation opportunity	Competitive status
Mylotarg	Anti-CD33 antibody-drug conjugate	Liquid stability, reduced reconstitution, biosimilar formulation	Established FDA-approved product
Conventional chemotherapy	Small molecules	Oral or infusion convenience	Broad AML use but different mechanism
CD33 bispecific antibodies	Biologic	Low-dose liquid presentation and infusion management	Development-stage or emerging competition
CD33 cellular therapies	Cell therapy	Cryopreservation and logistics	Development-stage
Other ADC platforms	Antibody-drug conjugates	Payload, linker, and conjugation differentiation	Competitive development field

Mylotarg's primary formulation advantage is its established clinical use and manufacturing platform. Its weakness is operational complexity compared with a stable liquid biologic or an oral therapy.

What generic launch risks exist for Mylotarg?

A conventional generic launch is not the likely pathway. The relevant entry scenario is a biosimilar or follow-on biologic.

Entry scenario	Probability driver	Commercial effect
No biosimilar before meaningful patent clearance	Complex ADC characterization and limited market size	Pfizer retains pricing control
Biosimilar with a distinct formulation	Lower preparation burden or improved stability	Hospital conversion may depend on handling economics
Interchangeable biosimilar	FDA interchangeability determination and pharmacy policy	Greater substitution potential
Competing CD33 therapy	Superior safety, dosing, or logistics	Could reduce Mylotarg demand without direct biosimilar substitution
Reformulated originator product	Improved presentation by Pfizer	Could extend commercial differentiation

Mylotarg's relatively specialized AML market may limit the return on a biosimilar investment. The commercial case improves if a developer can use the same manufacturing platform for other ADCs or obtain a contract manufacturing and formulation partnership.

What licensing deals could support Mylotarg reformulation?

The most practical licensing models are:

1. Excipient technology license for low-peroxide surfactants or stabilizer systems
2. CDMO partnership for liquid ADC development
3. Device or container-closure license for pharmacy-ready administration
4. Biosimilar development partnership with an oncology company
5. Regional commercialization license tied to improved presentation
6. Manufacturing technology transfer for conjugation and fill-finish

An excipient supplier would have stronger negotiating leverage if it can demonstrate performance in ADCs rather than conventional monoclonal antibodies. A formulation company would need a patent position covering the specific Mylotarg-like composition and supporting stability data.

Key Takeaways

• Mylotarg uses a lyophilized formulation containing sucrose, dextran 40, polysorbate 80, and sodium chloride.
• The highest-value formulation opportunity is a stable liquid or pharmacy-ready presentation.
• Dextran reduction and polysorbate replacement are credible technical development targets.
• Mylotarg is a BLA biologic, so conventional Orange Book and Paragraph IV strategies do not apply.
• Biosimilar development is technically difficult because Mylotarg is an antibody-drug conjugate with linker, payload, and drug-antibody ratio complexity.
• A formulation patent needs comparative evidence showing improved stability, handling, recovery, or safety-related performance.
• Pediatric dosing and single-dose vial waste create targeted commercial opportunities.
• Manufacturing know-how and analytical comparability may remain meaningful barriers after basic composition patents expire.

FAQs

Can Mylotarg be reformulated without changing its FDA-approved indication?

Yes, but a significant formulation change would require regulatory review under the BLA framework. The sponsor would need to demonstrate comparability and assess pharmacokinetic, immunogenicity, safety, and stability effects.

Is dextran 40 essential to Mylotarg stability?

The approved formulation uses dextran 40, but the excipient is not necessarily irreplaceable. Substitution would require evidence that the alternative maintains cake structure, reconstitution, aggregation control, potency, and conjugate integrity.

Could a Mylotarg biosimilar use polysorbate 20 instead of polysorbate 80?

Potentially. A biosimilar does not generally need to duplicate every excipient, but the alternative surfactant must support a highly similar product and must not create clinically meaningful differences.

Would a ready-to-use Mylotarg product qualify for new patent protection?

It could, if the presentation has patentable technical features such as a defined liquid composition, stability profile, container system, concentration range, or administration configuration. Known excipients alone would rarely provide strong protection.

Does Mylotarg have a conventional generic drug market?

No. The relevant competitive pathway is a biosimilar or follow-on biologic pathway, not an abbreviated new drug application for a conventional small-molecule generic.

References

1. U.S. Food and Drug Administration. (2022). Mylotarg (gemtuzumab ozogamicin) prescribing information. Pfizer Inc. https://labeling.pfizer.com/ShowLabeling.aspx?id=9548

2. U.S. Food and Drug Administration. (2010). FDA statement on the voluntary withdrawal of Mylotarg. https://www.fda.gov

3. U.S. Food and Drug Administration. (2017). FDA approves Mylotarg for treatment of acute myeloid leukemia. https://www.fda.gov/news-events/press-announcements/fda-approves-mylotarg-treatment-acute-myeloid-leukemia

4. U.S. Food and Drug Administration. (2023). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

5. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §7002.